Our findings revealed the therapeutic efficacy of SQJZ capsule in alleviating CKD by inhibiting intestinal inflammation and elucidated its possible mechanistic involvement of CHAC1 and HIF-1 signaling, not only providing experimental evidence for SQJZ as a gut-targeted therapy for CKD but also suggesting CHAC1 as a potential therapeutic target for CKD-associated intestinal inflammation. Here, HIF1A is linked to chronic kidney disease.